Loading…
← CockpitCompetitor Analysis › 600664.SS Harbin Pharmaceutical Group Co., Ltd. Class AOpen in the cockpit ↗

Harbin Pharmaceutical Group Co., Ltd. Class A600664.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Large Chinese state pharma group making antibiotics, vitamins (incl. bulk vitamin C) and OTC medicines.

Momentum strong 60
Mkt cap
$1.78B
US dollars, full cap
Free float
48%
of shares outstanding
$/day
$196M
20-day average traded
Fwd P/E
19.7×
forward earnings
ROIC−WACC
+6.0 pp
WACC 5.0%
Hurdle
-13 pp
Req g minus delivered
Next earnings
147 days
14 Apr 2027
Close · CNYCN¥4.81
1D-0.8%
1W-16.2%
1M-17.9%
3M-45.7%
6M+32.1%
YTD+39.4%
1Y+31.4%
ATR %7.9%
52w lowhigh51.2% off high

What Harbin Pharmaceutical does

Large Chinese state pharma group making antibiotics, vitamins (incl. bulk vitamin C) and OTC medicines.

Bulk vitamin C is a commodity whose price follows global supply, with China dominating output, so profit swings. Branded OTC medicines and antibiotics provide steadier but slower-growing income.

Products and services

  • Bulk vitamin C/pharma chemicals
  • Antibiotics
  • OTC medicines

Customers

  • Global pharma/food companies (bulk vitamin C)
  • Hospitals/pharmacies

Where it sits in the supply chain

  • Health Care
  • Pharmaceuticals
  • Antibiotics + vitamins + OTC

What could go right

  • Bulk vitamin/API demand growth

What could go wrong

  • Commodity API/vitamin price cycles
  • Antibiotic price competition

Moat: narrow (scale). Large-scale bulk API/vitamin manufacturing versus smaller regional producers.

Headquarters: Harbin, China · Employees: 10,039

Named competitors

Harbin Pharmaceutical at a glance

Size Harbin Pharmaceutical (600664.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.78B, the 1292nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥4.81 on 18 Nov 2026.

Performance Over six months the shares gained 32.1%, against -7.3% for the median peer and -20.0% for the China market (cap-weighted) — 2nd highest of 21 in its peer set.

Growth Revenue grew 2.2% over the last twelve months (peer median +9.0%); the operating margin is 5.1% (peer median 7.8%).

Valuation It trades at 19.7× forward earnings against a peer median of 17.4× (8th most expensive of 18).

Price implies For today's price to make sense, revenue must grow about -5% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -13 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 6.0 points above its cost of capital (5.0% WACC).

Next results Next results expected around 14 Apr 2027 (exchange calendar; dates can move).

Relative performance

10020021 May 202621 Aug 202618 Nov 2026600664.SS 136Peer median 95
Six months, rebased to 100: Harbin Pharmaceutical against the median of its 20 peers (local-currency closes).

Harbin Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥16.3BCN¥15.9BCN¥16.1BCN¥15.3BCN¥13.7B
Revenue growth—-1%+5%+12%—
Gross profitCN¥4.36BCN¥3.95BCN¥4.35BCN¥3.77BCN¥3.10B
EBITDAn/aCN¥845MCN¥1.22BCN¥919MCN¥871M
Net incomeCN¥633MCN¥362MCN¥629MCN¥395MCN¥465M
Free cash flowCN¥724MCN¥289MCN¥692MCN¥864MCN¥533M
Capital expenditureCN¥176MCN¥151MCN¥101MCN¥86.5MCN¥89.6M
Total debtCN¥2.56BCN¥2.94BCN¥3.78BCN¥3.56BCN¥3.43B

Quarterly statements and history in the cockpit →

Harbin Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%-10%0%+10%ETON9989AGIO3933301015RAREZYME000028605507300573NATCOPHARMDMP000908688166MAZEFAE300723CAPLIPOINT600211600664.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Harbin Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×50×100×150×ETON99893933301015RAREZYME300573NATCOPHARMDMP688166FAE300723COHANCECAPLIPOINT600664.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Harbin Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%0%200%ETON99893933NATCOPHARM600664.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Harbin Pharmaceutical is the large dot.

Harbin Pharmaceutical competitors and peer comparison

Head to head with its named competitors (600664.SS vs 600812.SS vs 1093.HK vs 000597.SZ)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Harbin Pharmaceutical 600664.SS$1.78B+32%+2%5%19.7×-5.3%
North China Pharmaceutical 600812.SS$1.08B-12%-21%5%n/a1.0%
Cspc Pharma 1093.HK$12.0B+10%+25%28%9.1×-10.7%
Northeast Pharmaceutical 000597.SZ$895M-14%-6%3%n/a-7.6%
Zhejiang Medicine 600216.SS$1.51B-26%-6%7%11.5×-7.8%
Shandong Xinhua Pharmaceutical 000756.SZ$1.01B-17%-5%4%20.0×0.5%
Zhejiang NHU 002001.SZ$11.8B-22%+11%33%9.7×-8.3%

How Harbin Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Harbin Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure600664.SSPeer medianRank in peer set
1-month return-17.9%+0.1%2nd lowest of 21
6-month return+32.1%-7.3%2nd highest of 21
Distance from 52-week high-51.2%-32.8%4th lowest of 21
Revenue growth (TTM)+2.2%+9.0%9th lowest of 21
Operating margin5.1%7.8%9th lowest of 21
Forward P/E19.7×17.4×8th most expensive of 18
Growth the price implies (Req g, 7 yrs)-5.3%4.6%3rd least demanding of 15
Growth delivered (Del g)+8.2%+8.6%8th highest of 15
Hurdle (Req g minus delivered)-13.4 pp-6.4 pp5th least demanding of 15
ROIC minus cost of capital+6.0 pp-2.9 pp4th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Harbin Pharmaceutical 600664.SSChina$1.78B+32%+2%5%19.7×-5.3%+8.2%
Eton Pharmaceuticals ETONUnited States$1.79B+226%+101%29%24.6×21.9%+359.6%
Shenzhen Hepalink Pharmaceutical 9989.HKHong Kong$1.78B-13%-1%8%8.7×-0.4%-0.2%
Agios Pharmaceuticals AGIOUnited States$1.78B+4%+214%-298%n/an/an/a
United Laboratories International 3933.HKHong Kong$1.80B-20%-13%5%13.0×1.2%+7.8%
Qingdao Baheal Medical 301015.SZChina$1.81B+2%-6%8%21.0×10.1%+5.0%
Ultragenyx Pharmaceutical RAREUnited States$1.81B-24%+16%-64%9.6×n/an/a
Zymeworks ZYMEUnited States$1.81B+5%+98%17%160.4×n/an/a
China National Accord Medicines 000028.SZChina$1.81B-3%0%2%10.8×-9.5%+4.2%
Guobang Pharma 605507.SSChina$1.82B-6%+3%12%15.7×-6.0%+7.4%
Shenyang Xingqi Pharmaceutical 300573.SZChina$1.83B-25%+17%33%13.0×5.4%+29.1%
NATCO Pharma NATCOPHARM.NSIndia$1.73B-27%-30%17%19.1×20.5%+19.0%
Dermapharm DMP.DEGermany$1.85B-29%+2%21%13.2×-3.4%+8.0%
CSPC Hunan Jingfeng Pharmaceutical 000908.SZChina$1.85B-38%+5%-18%n/an/an/a
BrightGene Bio-Medical Technology 688166.SSChina$1.71B-57%+14%7%74.9×35.3%+9.2%
Maze Therapeutics MAZEUnited States$1.71B+27%-100%-821%n/an/an/a
Faes Farma FAE.MCSpain$1.71B+6%+32%14%17.4×3.7%+9.9%
ApicHope Pharmaceutical 300723.SZChina$1.70B-36%-28%-50%22.0×11.3%-11.0%
Cohance Lifesciences COHANCE.NSIndia$1.87B+7%+14%2%96.3×n/an/a
Caplin Point Laboratories CAPLIPOINT.NSIndia$1.70B+2%+17%31%21.4×24.3%+15.7%
Tibet Rhodiola Pharmaceutical 600211.SSChina$1.87B-8%+13%27%12.5×-1.2%+16.7%

Questions

Who are Harbin Pharmaceutical's main competitors?
Named competitors: North China Pharmaceutical (600812.SS), CSPC Pharmaceutical Group (1093.HK), Northeast Pharmaceutical (000597.SZ), Zhejiang Medicine (600216.SS), Shandong Xinhua Pharmaceutical (000756.SZ), Zhejiang NHU (002001.SZ). The cockpit's measured peer set (industry) also includes Eton Pharmaceuticals (ETON), Shenzhen Hepalink Pharmaceutical (9989.HK), Agios Pharmaceuticals (AGIO), United Laboratories International (3933.HK), Qingdao Baheal Medical (301015.SZ), Ultragenyx Pharmaceutical (RARE).
Is Harbin Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 19.7× against a peer median of 17.4×, 8th most expensive of 18 in its peer set. For today's price to make sense, revenue must grow about -5% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -13 pp: the price already allows for a slowdown.
How has Harbin Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned +32.1% against -7.3% for the median peer; over one year +31.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.